339-42-4

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-N-[4-(TRIFLUOROMETHYL)PHENYL]BENZENESULFONAMIDE, TECH is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, enhancing their therapeutic properties and effectiveness.
Used in Agrochemical Industry:
In the agrochemical sector, 4-AMINO-N-[4-(TRIFLUOROMETHYL)PHENYL]BENZENESULFONAMIDE, TECH serves as an intermediate in the production of agrochemicals, contributing to the development of more effective and targeted pesticides and other agricultural chemicals.
Used in Organic Synthesis:
4-AMINO-N-[4-(TRIFLUOROMETHYL)PHENYL]BENZENESULFONAMIDE, TECH is utilized as a reagent in organic synthesis, facilitating various chemical reactions and the formation of new compounds with desired properties.
Used in Dye and Pigment Production:
This chemical compound is used as a raw material in the production of dyes and pigments, where its unique structure contributes to the color and stability of the final products.
Used in Polymer, Plastic, and Rubber Industries:
4-AMINO-N-[4-(TRIFLUOROMETHYL)PHENYL]BENZENESULFONAMIDE, TECH is employed in the manufacturing of polymers, plastics, and rubber products, where it can improve the performance characteristics of these materials, such as their durability, flexibility, and resistance to environmental factors.

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 433-00-1 N-(4-(N-(4-(trifluoromethyl)phenyl)sulfamoyl)phenyl)acetamide 
• 312-51-6 N-((4-trifluoromethyl)phenyl)-4-nitrobenzene sulphonamide 
• 103-84-4 Acetanilid 
• 14505-17-0 p-nitrobenzylidyne tribromide 
• 402-54-0 p-nitrobenzotrifluoride 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1023311-08-1 4-isothiocyanato-N-(4-trifluoromethyl-phenyl)benzenesulfonamide 
• 1395084-39-5 (E)-4-( (4-hydroxy-3,5-dimethylphenyl)diazenyl)-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide 

Relevant academic research and scientific papers

Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors

In this work, we designed and synthesized 35 new triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives as P. falciparum inhibitors (3D7 strain). Thirty compounds exhibited anti-P. falciparum activity, with IC50 values ranging from 0.030 to 9.1 μM. The [1,2,4]triazolo[1,5-a]pyrimidine derivatives were more potent than the pyrazolo[1,5-a]pyrimidine and quinoline analogues. Compounds 20, 21, 23 and 24 were the most potent inhibitors, with IC50 values in the range of 0.030–0.086 μM and were equipotent to chloroquine. In addition, the compounds were selective, showing no cytotoxic activity against the human hepatoma cell line HepG2. All [1,2,4]triazolo[1,5-a]pyrimidine derivatives inhibited PfDHODH activity in the low micromolar to low nanomolar range (IC50 values of 0.08–1.3 μM) and did not show significant inhibition against the HsDHODH homologue (0–30% at 50 μM). Molecular docking studies indicated the binding mode of [1,2,4]triazolo[1,5-a]pyrimidine derivatives to PfDHODH, and the highest interaction affinities for the PfDHODH enzyme were in agreement with the in vitro experimental evaluation. Thus, the most active compounds against P. falciparum parasites 20 (R = CF3, R1 = F; IC50 = 0.086 μM), 21 (R = CF3; R1 = CH3; IC50 = 0.032 μM), 23, (R = CF3, R1 = CF3; IC50 = 0.030 μM) and 24 (R = CF3, 2-naphthyl; IC50 = 0.050 μM) and the most active inhibitor against PfDHODH 19 (R = CF3, R1 = Cl; IC50 = 0.08 μM - PfDHODH) stood out as new lead compounds for antimalarial drug discovery. Their potent in vitro activity against P. falciparum and the selective inhibition of the PfDHODH enzyme strongly suggest that this is the mechanism of action underlying this series of new [1,2,4]triazolo[1,5-a]pyrimidine derivatives.

Sulphonamidic Groups as Electron-Withdrawing Units in Ureido-Based Anion Receptors: Enhanced Anion Complexation versus Deprotonation

A sulphonamidic moiety was utilized as an electron-withdrawing group for enhancement of anion complexation features of urea-based receptors. A series of receptors varying in acidity of sulphonamidic and urea NH groups was synthesized and thoroughly tested. The individual complexation properties reflect deprotonation/complexation equilibrium in a given molecule as a function of the substitution. The receptors containing electron-donating groups in conjugation to the sulphonamidic moiety showed higher association constants towards H2PO4? and carboxylate anions, while those containing electron-withdrawing groups inclined to deprotonation of sulphonamidic NH. The deprotonation issue can be avoided by alkylation at the early step of receptor synthesis or it can be utilized for insertion of suitable groups that enable its anchoring on various substrates to form more elaborated receptor structures.

Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains

BRD4, characterized by two acetyl-lysine binding bromodomains and an extra-terminal (ET) domain, is a key chromatin organizer that directs gene activation in chromatin through transcription factor recruitment, enhancer assembly, and pause release of the RNA polymerase II complex for transcription elongation. BRD4 has been recently validated as a new epigenetic drug target for cancer and inflammation. Our current knowledge of the functional differences of the two bromodomains of BRD4, however, is limited and is hindered by the lack of selective inhibitors. Here, we report our structure-guided development of diazobenzene-based small-molecule inhibitors for the BRD4 bromodomains that have over 90% sequence identity at the acetyl-lysine binding site. Our lead compound, MS436, through a set of water-mediated interactions, exhibits low nanomolar affinity (estimated Ki of 30-50 nM), with preference for the first bromodomain over the second. We demonstrated that MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages. MS436 represents a new class of bromodomain inhibitors and will facilitate further investigation of the biological functions of the two bromodomains of BRD4 in gene expression.

Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors

In order to create novel analgesic agents without gastric disturbance, structurally simple cyclooxygenase-1 (COX-1) inhibitors with a benzenesulfonanilide skeleton were designed and synthesized. As a result, compounds 11f and 15a, which possess a p-amino group on the benzenesulfonyl moiety and p-chloro group on the anilino moiety, showed COX-1-selective inhibition. Moreover compound 11f, which is the most potent compound in this study showed more potent analgesic activity than that of aspirin at 30 mg/kg by po. The anti-inflammatory activity and gastric damage, however, were very weak or not detectably different from aspirin. Since the structure of our COX-1 inhibitors are very simple, they may be useful as lead compounds for superior COX-1 inhibitors as analgesic agents without gastric disturbance.

Trifluoromethylcontaining sulfanilamides. I. Synthesis and in vitro antibacterial activity

In a wider research directed to improve pharmacological profiles of known antiinfective agents by introducing fluorine or trifluoromethyl groups, some sulfanilamides trifluoromethylsubstituted on N1 ring, were synthesized and examined for their